Smith & Nephew acquired BST-CarGel® cartilage repair product and IP assets from Piramal. Transaction terms were not disclosed.
BST-CarGel is employed with microfracture and bone marrow stimulation techniques for initial treatment of most sizes of focal cartilage tears. It can be delivered arthroscopically and acts as a scaffold to treat damage in synovial joints such as the knee, hip, ankle and shoulder. The scaffold adheres to the cartilage surface, stabilizing the blood clot while new cartilage regenerates.
BST-CarGel is cleared for use in most geographies (including Australia, Canada and most of the EU).
Piramal acquired Biosyntech, developer of BST-CarGel, in 2Q10 for for CAN $3.9MM (~US $3.6MM). In 2012, Piramal announced results from an international multicenter Phase III clinical trial suggesting that cartilage repair using BST-CarGel resulted in more repaired cartilage of higher quality than treatment via microfracture, with a similar safety profile. (Additional study notes are available at clinicaltrials.gov.)
Smith & Nephew acquired BST-CarGel® cartilage repair product and IP assets from Piramal. Transaction terms were not disclosed.
BST-CarGel is employed with microfracture and bone marrow stimulation techniques for initial treatment of most sizes of focal cartilage tears. It can be delivered arthroscopically and acts as a scaffold to treat...
Smith & Nephew acquired BST-CarGel® cartilage repair product and IP assets from Piramal. Transaction terms were not disclosed.
BST-CarGel is employed with microfracture and bone marrow stimulation techniques for initial treatment of most sizes of focal cartilage tears. It can be delivered arthroscopically and acts as a scaffold to treat damage in synovial joints such as the knee, hip, ankle and shoulder. The scaffold adheres to the cartilage surface, stabilizing the blood clot while new cartilage regenerates.
BST-CarGel is cleared for use in most geographies (including Australia, Canada and most of the EU).
Piramal acquired Biosyntech, developer of BST-CarGel, in 2Q10 for for CAN $3.9MM (~US $3.6MM). In 2012, Piramal announced results from an international multicenter Phase III clinical trial suggesting that cartilage repair using BST-CarGel resulted in more repaired cartilage of higher quality than treatment via microfracture, with a similar safety profile. (Additional study notes are available at clinicaltrials.gov.)
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
